Fox Run Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Fox Run Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,792	Closed	-$335K	–	966
2018 Q1	$335K	Buy	+25,792	New	+$384K	0.08%	457
2017 Q3	–	Sell	-8,300	Closed	-$200K	–	924
2017 Q2	$200K	Buy	+8,300	New	+$183K	0.07%	538

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's PRTK Position: Q2 2018 in Review

Fox Run Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2018, closing a stake of 25,792 shares — an estimated $335K sold.

Fox Run Management first reported a position in PRTK in Q2 2017 and held it in 2 quarters. The position peaked at $335K in Q1 2018. 110 funds tracked by Wall St. Rank hold PRTK as of Q2 2018.

Fox Run Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Fox Run Management sold 25,792 Paratek Pharmaceuticals, Inc. shares in Q2 2018, an estimated $335K.
Fox Run Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Fox Run Management's Paratek Pharmaceuticals, Inc. position peaked at $335K in Q1 2018.
110 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2018.

Based on Fox Run Management's 13F filing for Q2 2018, filed 17 Jul 2018.